Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study

Table 15 Summary of clinical outcomes and longitudinal laboratory trends

Outcome/parameter	DAA-Treated (n = 118)	Non-DAA (n = 112)	P value
Variceal rebleeding, n (%)	12 (10.2)	31 (27.7)	0.001
Liver transplantation, n (%)	4 (3.4)	9 (8.0)	0.12
Liver-related mortality, n (%)	5 (4.2)	14 (12.5)	0.032
MELD score (baseline)	9 (8-10)	9 (7-10)	0.50
MELD score (36 months)	8 (7-10)	10 (9-12)	0.002
Platelets (baseline, × 10³/μL)	156 ± 40	166 ± 38	0.11
Platelets (36 months)	165 ± 42	148 ± 36	0.015

MELD: Model for end-stage liver disease; DAA: Direct-acting antiviral.